LG Chem said it would accelerate developing immunotherapies to treat various solid cancers and blood cancers in collaboration with Cue Biopharma, a U.S. immunotherapy developer.Cue Biopharma has recently completed preclinical trials of CUE-102 and has selected final candidates for full-scale clinica
CJ Bioscience, a subsidiary of CJ CheilJedang specializing in the “red bio” business of pharmaceutical and healthcare business, was officially launched Tuesday.The new company vowed to develop microbiome-based new drugs and strengthen its competitiveness in the wellness business to grow as the group
Drug recalls due to the detection of NDMA (N-nitrosodimethylamine) impurities in nizatidine-based drugs have continued through 2022.On Monday, the Ministry of Food and Drug Safety issued a recall order for a batch of Medica Korea’s Zatidine Capsule 150mg (Nizatidine) and Hutecs Korea Pharmaceutical’
Hanmi Pharmaceutical is drawing attention after changing the terms of a technology transfer agreement with Spectrum, a U.S. partner developing its anticancer drugs poziotinib and Rolontis.Industry insiders have interpreted the change in the agreement between the two companies to reduce Spectrum's in
Curocell said Monday that it has attracted 36 billion won ($30 million) of pre-initial public offering (IPO) investment, 16 months after it attracted Series C investment in 2020.Among existing investment institutions, Stic Ventures, DS Asset Management, Seoul Investment Partners, Ryukyung PSG Asset
GC Cell said that it has signed a technology export contract for Immuncell-LC, an immunotherapy candidate, with Rivaara Immune Private Limited, an Indian pharmaceutical company.Under the accord, GC Cell will provide clinical results, production technology, quality testing methods, and know-how of Im
Chlorthalidone, recommended as a first-line treatment in Korean and foreign hypertension treatment guidelines, may expand its use after a study showed its efficacy in lowering blood pressure in people with moderate-to-severe chronic kidney disease (CKD).Researchers at Indiana Medical University in t
Three Sanofi offshoots in Korea – Sanofi-Aventis Korea, Sanofi Pasteur, and Opella Healthcare Korea – will change the way their employees work under their headquarters’ new strategy of “reinvent how we work,” Sanofi-Aventis said Monday.The new strategy, called “WEWE” (When Ever Where Ever), aims to
Tego Science’s cell therapy product, TPX-115, has shown more excellent efficacy than platelet-rich plasma (PRP) treatment, a local research team said Monday based on a trial using an animal model.The non-clinical thesis to that effect, written by a group of researchers led by Professor Oh Ju-han of
Hanmi Pharmaceutical said it has transferred rights for Luminate (ingredient: Risuteganib), an innovative new drug in ophthalmology, to AffaMed Therapeutic, a Chinese-based pharmaceutical company.Luminate is a new retinal disease drug developed by Allegro Ophthalmics, a U.S.-based R&D company specia
DongWha Pharm has obtained the approval for its new oral digestive medicine, Whaljjakjeong, once again.Industry watchers are paying attention to whether the digestive pill, which had failed to make its commercial debut over the past four years since it won the initial permission, will be able to cro
LegoChem Bioscience and ABL Bio said Monday that their global partner CStone Pharmaceuticals has received investigational new drug (IND) approval for CS5001, antibody-drug conjugate (ADC) anticancer drug candidate jointly developed by the two Korean companies.LegoChem Bio licensed out the developmen
Daewoong Pharmaceutical said that it has submitted a biologics license application (BLA) for its botulinum toxin (BTX) product Nabota treating forehead wrinkles to China’s National Medical Products Administration (NMPA).Daewoong completed the phase 3 clinical trial of Nabota in China in July under t
A day after Biogen's stock price jumped upon news that Samsung Group was in talks to acquire the Boston-based biotech, the Korean conglomerate group denied the media report as “not true.”The Korea Economic Daily, a vernacular financial paper, reported on Thursday that Samsung Group is reportedly neg
Daewoong Pharmaceutical said Thursday that its Fexuclue has won regulatory approval as a new drug for gastroesophageal reflux disease (GERD).The company said the Ministry of Food and Drug Safety authorized 40 milligrams of Fexuclue for erosive GERD. It plans to apply for setting the share of insuran
The Samsung Group is reportedly negotiating with Biogen to buy out the U.S. pharmaceutical company in a deal that may be worth up to $42 billion, according to a vernacular financial paper citing investment banking sources.On Wednesday, the Korea Economic Daily reported that if the deal is confirmed,
Yuhan Corp. has registered the patent of Esopid Tab. (esomeprazole magnesium trihydrate/calcium carbonate), a treatment for gastroesophageal reflux disease (GERD), to block the entry of latecomers and counter rivals in the proton pump inhibitor (PPI) plus antacid combination therapy market.Industry
Moderna, a biotech company developing messenger RNA (mRNA) therapeutics, has revealed a revised agreement to supply 20 million doses of its Covid-19 vaccines and updated booster candidates to Korea in 2022.Under the new accord, the company will provide 15 million doses for delivery in the third quar
Vivozon Pharmaceutical, which was punished for making drugs in unauthorized methods earlier this year, has been recently ordered to recall and discard medicines due to the same GMP violation.The Ministry of Food and Drug Safety said on Monday that it would urgently request a recall of two medicines
An increasing number of Korean pharmaceutical and biotech companies are collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to tap the global vaccine market.CEPI is an international private organization established in 2017 to support vaccine development to fight infectious